AI English summary of an SEC filing — figures as filed
Zoetis ZTSZoetis said revenue for Q4 2024 was $2.3 billion, growing 5% compared with the prior-year quarter, and net income was $581 million, or $1.29 per diluted share, increasing 11% and 13%, respectively. On an operational basis, revenue growth was 6%.
Key points
AI summaryZoetis said revenue for Q4 2024 was $2.3 billion, growing 5% compared with the prior-year quarter, and net income was $581 million, or $1.29 per diluted share, increasing 11% and 13%, respectively. On an operational basis, revenue growth was 6%.
The company reported revenue of $9.3 billion for 2024, growing 8% on a reported basis and 11% operationally, and net income of $2.5 billion, or $5.47 per diluted share. Adjusted net income was $2.7 billion, or $5.92 per diluted share, excluding the net impact of $207 million for purchase accounting adjustments, acquisition and divestiture-related costs, and certain significant items.
Zoetis completed the divestiture of its medicated feed additive product portfolio, certain water soluble products and related assets on October 31, 2024. Organic operational revenue growth, which excludes the impact of divested products and foreign exchange, was 9% for Q4 and 12% for the full year.
The company said it is providing full-year 2025 guidance of revenue between $9.225 billion and $9.375 billion, with organic operational growth of 6% to 8%. Reported diluted EPS is expected to be between $5.70 and $5.80, or between $6.00 and $6.10 on an adjusted basis. This guidance reflects foreign exchange rates as of January 2025.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.
Q4 2024 Revenue $2.3 billion, Net Income $581 million
Zoetis said revenue for Q4 2024 was $2.3 billion, growing 5% compared with the prior-year quarter, and net income was $581 million, or $1.29 per diluted share, increasing 11% and 13%, respectively. On an operational basis, revenue growth was 6%.
Source · Based on the filing body and exhibits
Full-Year 2024 Revenue $9.3 billion, Adjusted Net Income $2.7 billion
The company reported revenue of $9.3 billion for 2024, growing 8% on a reported basis and 11% operationally, and net income of $2.5 billion, or $5.47 per diluted share. Adjusted net income was $2.7 billion, or $5.92 per diluted share, excluding the net impact of $207 million for purchase accounting adjustments, acquisition and divestiture-related costs, and certain significant items.
Source · Based on the filing body and exhibits
Divestiture of Medicated Feed Additive Product Portfolio and Organic Operational Growth
Zoetis completed the divestiture of its medicated feed additive product portfolio, certain water soluble products and related assets on October 31, 2024. Organic operational revenue growth, which excludes the impact of divested products and foreign exchange, was 9% for Q4 and 12% for the full year.
Source · Based on the filing body and exhibits
Full-Year 2025 Guidance
The company said it is providing full-year 2025 guidance of revenue between $9.225 billion and $9.375 billion, with organic operational growth of 6% to 8%. Reported diluted EPS is expected to be between $5.70 and $5.80, or between $6.00 and $6.10 on an adjusted basis. This guidance reflects foreign exchange rates as of January 2025.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…